T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.11B |
| 2 |
Meta Platforms (Facebook)
META
|
+$2.59B |
| 3 |
EQT Corp
EQT
|
+$1.31B |
| 4 |
Colgate-Palmolive
CL
|
+$1.08B |
| 5 |
Adobe
ADBE
|
+$1.06B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.92B |
| 2 |
UnitedHealth
UNH
|
+$1.78B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.55B |
| 4 |
Ross Stores
ROST
|
+$1.54B |
| 5 |
ASML
ASML
|
+$1.49B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.61% |
| 2 | Healthcare | 16.91% |
| 3 | Consumer Discretionary | 11.05% |
| 4 | Financials | 10.6% |
| 5 | Communication Services | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
826
Champion Homes
SKY
$5.23B
| $32.1M | ﹤0.01% |
489,793
+10,488
| +2% | +$713K |
|
827
Academy Sports + Outdoors
ASO
$3.03B
| $32.1M | ﹤0.01% |
593,076
-1,999
| -0.3% | -$115K |
|
828
APA Corp
APA
$14B
| $31.8M | ﹤0.01% |
930,419
-61,691
| -6% | -$2.15M |
|
829
Diageo
DEO
$52.8B
| $31.1M | ﹤0.01% |
179,450
-4,677
| -3% | -$835K |
|
830
LyondellBasell Industries
LYB
$20.2B
| $31M | ﹤0.01% |
337,606
-2,682
| -0.8% | -$245K |
|
831
Sana Biotechnology
SANA
$1.1B
| $30.5M | ﹤0.01% |
5,123,428
+612,642
| +14% | +$3.53M |
|
832
Braze
BRZE
$3.36B
| $30.3M | ﹤0.01% |
692,967
+217,574
| +46% | +$7.39M |
|
|
RETA
833
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $30.2M | ﹤0.01% |
295,741
-1,324
| -0.4% | -$125K |
|
834
MaxLinear
MXL
$6.95B
| $30M | ﹤0.01% |
949,242
-2,409
| -0.3% | -$69.6K |
|
835
QuidelOrtho
QDEL
$1.03B
| $29.9M | ﹤0.01% |
360,779
-148,827
| -29% | -$13M |
|
|
IGMS
836
DELISTED
IGM Biosciences
IGMS
| $29.8M | ﹤0.01% |
3,230,870
+1,109,995
| +52% | +$12.4M |
|
837
Flowserve
FLS
$10.3B
| $29.7M | ﹤0.01% |
800,740
-5,448
| -0.7% | -$189K |
|
838
Omnicell
OMCL
$1.72B
| $29.7M | ﹤0.01% |
403,526
-2,765
| -0.7% | -$186K |
|
839
Hewlett Packard
HPE
$79.2B
| $29.5M | ﹤0.01% |
1,753,328
+10,055
| +0.6% | +$154K |
|
840
Cirrus Logic
CRUS
$6.08B
| $29.3M | ﹤0.01% |
361,834
+365
| +0.1% | +$30.2K |
|
841
Amphastar Pharmaceuticals
AMPH
$858M
| $29.1M | ﹤0.01% |
506,308
+37,888
| +8% | +$1.68M |
|
|
DEN
842
DELISTED
Denbury Inc.
DEN
| $28.9M | ﹤0.01% |
334,473
+310,910
| +1,319% | +$28.2M |
|
|
TWNK
843
DELISTED
Hostess Brands, Inc. Class A Common Stock
TWNK
| $28.8M | ﹤0.01% |
1,135,530
-51,035
| -4% | -$1.31M |
|
844
Northern Trust
NTRS
$34.8B
| $28.5M | ﹤0.01% |
384,404
-28,557
| -7% | -$2.19M |
|
845
Clorox
CLX
$12.9B
| $28.5M | ﹤0.01% |
179,032
-1,779
| -1% | -$287K |
|
846
Labcorp
LH
$26.2B
| $28.4M | ﹤0.01% |
136,954
+37
| +0% | +$7.18K |
|
|
ENV
847
DELISTED
ENVESTNET, INC.
ENV
| $28.2M | ﹤0.01% |
475,525
-2,351
| -0.5% | -$136K |
|
848
Constellium
CSTM
$3.95B
| $27.9M | ﹤0.01% |
1,621,385
+73,561
| +5% | +$1.13M |
|
849
DraftKings
DKNG
$12.6B
| $27.8M | ﹤0.01% |
1,045,171
+97,573
| +10% | +$2.25M |
|
|
DAWN
850
DELISTED
Day One Biopharmaceuticals
DAWN
| $27.6M | ﹤0.01% |
2,309,731
+644,980
| +39% | +$8.42M |
|
Similar funds
T. Rowe Price Associates's Q2 2023 Portfolio in Review
As of Q2 2023, T. Rowe Price Associates held 3,044 positions worth $718B, up 7.4% from $668B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2023 filing shows 123 new, 1,636 increased, 968 reduced and 150 closed positions. Its largest new stake was Kenvue: 26,317,608 shares worth $695M. The largest sale was Microsoft, an estimated $1.92B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2023 buy was Kenvue: 26,317,608 shares worth $695M.
- T. Rowe Price Associates added most to Amazon in Q2 2023, an estimated $3.11B increase.
- T. Rowe Price Associates's biggest Q2 2023 reduction was Microsoft, cutting an estimated $1.92B.
- T. Rowe Price Associates fully exited Canadian Natural Resources in Q2 2023, selling an estimated $112M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $718B portfolio in Q2 2023.
- T. Rowe Price Associates opened 123 new positions and closed 150 in Q2 2023.
- T. Rowe Price Associates's portfolio value rose 7.4% quarter-over-quarter to $718B.
Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.